Australia's BCAL Diagnostics launches early detection cancer platform, shares rise
19/05/2026 04:50
** BCAL Diagnostics BDX.AX shares rise as much as 24.7% to A$0.096, their highest level since April 2 ** Health care co launches national referral infrastructure to support access to its early cancer detection test portfolio and scale commercial distribution ** About 604,582 shares traded so far, 5.1x 30-day ** Stock down 23.8% this year, including day's move (Reporting by Sherin Sunny in Bengaluru) ((Sherin.Sunny@thomsonreuters.com))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures